Report cover image

Anti-Obesity Drugs Market Growth, Size, Trends Analysis - By Type, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Feb 13, 2025
Length 229 Pages
SKU # SPER19805282

Description

Anti-Obesity Drugs Market Introduction and Overview

According to SPER Market Research, ‘Global Anti-Obesity Drugs Market Size – By Type, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Anti-Obesity Drugs Market is predicted to reach 79.26 billion by 2034 with a CAGR of 27.24%

Anti-obesity drugs are pharmaceutical treatments developed to combat excessive weight gain and the associated health complications, such as diabetes, hypertension, cardiovascular diseases, and certain cancers. These drugs work through various mechanisms, including appetite suppression, enhanced fat metabolism, and reduced calorie absorption, offering a solution for individuals who struggle to lose weight through diet and exercise alone.

Restraints: The market for anti-obesity medications has a number of obstacles in spite of its promise. Accessibility is restricted by the high expense of pharmaceuticals, particularly in low- and middle-income nations. Patients and healthcare professionals are discouraged from widespread adoption by safety concerns, which include side effects including cardiovascular risks or gastrointestinal problems. Critical obstacles include limited long-term efficacy and the considerable risk of weight return following therapy discontinuation.

Scope of the Report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Type, By Distribution Channel.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novo Nordisk A/S, Pfizer Inc, Sandoz International GmbH, VIVUS LLC. and others.

Anti-Obesity Drugs Market Segmentation:

By Type: Based on the Type, Global Anti-Obesity Drugs Market is segmented as; Prescription Drugs and OTC Drugs.

By Distribution Channel: Based on the Distribution Channel, Global Anti-Obesity Drugs Market is segmented as; Hospital Pharmacy and Online & Retail Pharmacy.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

229 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Anti-Obesity Drugs Market Manufacturing Base Distribution, Sales Area, Interface Type
6.2. Mergers & Acquisitions, Partnerships, Interface Launch, and Collaboration in Global Anti-Obesity Drugs Market
7. Global Anti-Obesity Drugs Market, By Type (USD Million) 2021-2034
7.1. Prescription Drugs
7.2. OTC Drugs
8. Global Anti-Obesity Drugs Market, By Distribution Channel (USD Million) 2021-2034
8.1. Hospital Pharmacy
8.2. Retail and Online Pharmacy
9. Global Anti-Obesity Drugs Market, (USD Million) 2021-2034
9.1. Global Anti-Obesity Drugs Market Size and Market Share
10. Global Anti-Obesity Drugs Market, By Region, (USD Million) 2021-2034
10.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
10.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. Boehringer Ingelheim International GmbH
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Interface summary
11.1.4. Recent developments
11.2. Currax Pharmaceuticals LLC
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Interface summary
11.2.4. Recent developments
11.3. F. Hoffmann-La Roche Ltd
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Interface summary
11.3.4. Recent developments
11.4. GlaxoSmithKline plc
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Interface summary
11.4.4. Recent developments
11.5. Novo Nordisk A/S
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Interface summary
11.5.4. Recent developments
11.6. Pfizer Inc
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Interface summary
11.6.4. Recent developments
11.7. Sandoz International GmbH
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Interface summary
11.7.4. Recent developments
11.8. VIVUS LLC
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Interface summary
11.8.4. Recent developments
11.9. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us